Randomized controlled clinical trials on the therapeutic effects of triamcinolone acetonide versus bevacizumab for diabetic macular edema

Randomized controlled clinical trials on the therapeutic effects of triamcinolone acetonide versus bevacizumab for diabetic macular edema - Randomized controlled clinical trials on the therapeutic effects of triamcinolone acetonide versus bevacizumab for diabetic macular edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009854

Enrollment

Registered

2013-01-25

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic macular edema

Interventions

Intravitreal injection of triamcinolone acetonide and follow up at least 6 months. Intravitreal injection of bevacizumab and follow up at least 6 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Aged 18 years or older. Diffuse DME(CMT 300microns < determined by OCT). Visual acuity: 1.0 logMAR >

Exclusion criteria

Exclusion criteria: Eyes with active proliferative DR. Eyes with known a history of glaucoma,optic nerve atrophy. History of laser photocoagulation within 3 months History of intravitreal injection or subrenon injection for diabetic macular edema within 3months. Aphakia Patients with any of serious heart disease, cerebrovascular disease,blood disorder, renal failure, malignant tumor, systemic steroids. Cases clear OCT images can not be obtained Patients with known as steroid responder.

Design outcomes

Primary

Measure	Time frame
visual acuity Foveal thickness and subfoveal choroidal thickness using optical coherent tomography	—

Secondary

Measure	Time frame
Frequency of recurrence Complications	—

Countries

Japan

Contacts

Public ContactShozo Sonoda

Kagoshima University Graduate School of Medical and Dental Science Department of Ophthalmology

shou@m3.kufm.kagoshima-u.ac.jp099-275-5402

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026